-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
As of now, the 2021 annual reports of pharmaceutical companies in the two cities have basically been disclosed, and the R&D investment of each company has also surfac.
According to incomplete statistics in the industry, a total of 247 pharmaceutical companies in the two cities have invested more than 100 million yuan in R&D, including BeiGene, Hengrui Medicine, Fosun Pharma, China Biopharmaceuticals, CSPC, Innovent Bio, Junshi Bio, e.
25 One company invested more than 1 billion yuan in research and development, and BeiGene ranked first with 538 billion yuan in research and development investme.
Over 80% of enterprises have increased investment in research and development, among which, 30 companies including Beihai Kangcheng, Huiyu Pharmaceutical, Zhaoke Ophthalmology, Zai Lab, Watson Bio, Kintor Pharmaceutical, Huluwa, Jichuan Pharmaceutical, and Pien Tze Huang have increased by more than 100% year-on-ye.
From the perspective of the ratio of R&D investment to revenue of 247 pharmaceutical companies, including unprofitable companies, a total of 17 R&D investment accounted for more than 100% of revenue, including BeiGene, Zai Lab, Acefang Bio, and Ascenta.
Medicine, Shenzhou Cell, Zejing Pharmaceutical, Corning Jerry Pharmaceutical, Occidental Biological, Beihai Kangcheng, MicroPort Robot, Connoya, Chuangsheng Group, Jiakesi, Maibo Pharmaceutical, TOT BIOPHARM, Ascletis Pharmaceuticals , Frontier Biology,e.
In addition, from the perspective of 31 companies with revenue exceeding 10 billion, 12 R&D investment accounted for more than 10% of revenue, namely Hengrui Pharmaceutical, Fosun Pharma, China Biopharmaceutical, CSPC, Mindray Medical, Shanghai Pharmaceuticals, Health Yuan, Kelun Pharmaceutical, Huadong Medicine, Lepu Medical, Changchun High-tech, Renfu Medicine,e.
Among them, Hengrui Medicine's R&D investment in 2021 will reach 203 billion yuan, and its revenue in the same year will reach 291 billion yu.
The proportion of R&D investment in revenue will exceed 20%, or about 2
As of the end of 2021, the company has 5,478 R&D personnel, accounting for 240% of the tot.
Hengrui Medicine's innovative capabilities and achievements have been continuously recognized by the international academic communi.
At the 2021 American Society of Clinical Oncology (ASCO) annual meeting, Hengrui Medicine has a total of 64 studies selected, of which 38 studies of camrelizumab alone , across 11 cancer typ.
In addition, a total of 28 papers have been published in top international academic journals such as The Lancet, Natural Medicine, e.
At the same time, under the continuous high investment in research and development, the innovative achievements of Hengrui Medicine have gradually entered the harvest peri.
In 2021, Hengrui Medicine will independently develop innovative drugs Haitrombopag Ethanolamine Tablets, Proline Henggliflozin Tablets, Isethionate Dalcili acid tablets were approved for marketi.
Up to now, the number of innovative drugs on the market has increased to 10, more than 60 innovative drugs are under clinical development, and more than 250 clinical trials are being carried out at home and abro.
The overseas market is a major layout of the compa.
In 2021, Hengrui Medicine will continue to strengthen the implementation of its internationalization strate.
During the reporting period, overseas R&D investment totaled 236 billion yuan, accounting for 193% of the total R&D investme.
At present, the company has a total of more than 170 overseas R&D tea.
During the reporting period, nearly 20 international clinical trials were carried out, and overseas registration applications were continu.
Following closely behind Hengrui are CSPC and Zhongsheng Pharmaceutical, with R&D investment of about 1
Among them, CSPC will invest 422 billion yuan in research and development in 2021, and achieve a revenue of 268 billion yuan (patented drugs), and its research and development investment will account for 11% of its revenue; Zhongsheng Pharmaceutical will invest 82 billion yuan in research and development in 2021, with a revenue of 286 billion yu.
, R&D investment accounted for 12% of reven.
In addition, Hansoh Pharmaceutical's revenue in 2021 is also approaching the 10 billion yuan mark, and its R&D investment in that year accounted for 11% of its reven.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
According to incomplete statistics in the industry, a total of 247 pharmaceutical companies in the two cities have invested more than 100 million yuan in R&D, including BeiGene, Hengrui Medicine, Fosun Pharma, China Biopharmaceuticals, CSPC, Innovent Bio, Junshi Bio, e.
25 One company invested more than 1 billion yuan in research and development, and BeiGene ranked first with 538 billion yuan in research and development investme.
Over 80% of enterprises have increased investment in research and development, among which, 30 companies including Beihai Kangcheng, Huiyu Pharmaceutical, Zhaoke Ophthalmology, Zai Lab, Watson Bio, Kintor Pharmaceutical, Huluwa, Jichuan Pharmaceutical, and Pien Tze Huang have increased by more than 100% year-on-ye.
From the perspective of the ratio of R&D investment to revenue of 247 pharmaceutical companies, including unprofitable companies, a total of 17 R&D investment accounted for more than 100% of revenue, including BeiGene, Zai Lab, Acefang Bio, and Ascenta.
Medicine, Shenzhou Cell, Zejing Pharmaceutical, Corning Jerry Pharmaceutical, Occidental Biological, Beihai Kangcheng, MicroPort Robot, Connoya, Chuangsheng Group, Jiakesi, Maibo Pharmaceutical, TOT BIOPHARM, Ascletis Pharmaceuticals , Frontier Biology,e.
In addition, from the perspective of 31 companies with revenue exceeding 10 billion, 12 R&D investment accounted for more than 10% of revenue, namely Hengrui Pharmaceutical, Fosun Pharma, China Biopharmaceutical, CSPC, Mindray Medical, Shanghai Pharmaceuticals, Health Yuan, Kelun Pharmaceutical, Huadong Medicine, Lepu Medical, Changchun High-tech, Renfu Medicine,e.
Among them, Hengrui Medicine's R&D investment in 2021 will reach 203 billion yuan, and its revenue in the same year will reach 291 billion yu.
The proportion of R&D investment in revenue will exceed 20%, or about 2
As of the end of 2021, the company has 5,478 R&D personnel, accounting for 240% of the tot.
Hengrui Medicine's innovative capabilities and achievements have been continuously recognized by the international academic communi.
At the 2021 American Society of Clinical Oncology (ASCO) annual meeting, Hengrui Medicine has a total of 64 studies selected, of which 38 studies of camrelizumab alone , across 11 cancer typ.
In addition, a total of 28 papers have been published in top international academic journals such as The Lancet, Natural Medicine, e.
At the same time, under the continuous high investment in research and development, the innovative achievements of Hengrui Medicine have gradually entered the harvest peri.
In 2021, Hengrui Medicine will independently develop innovative drugs Haitrombopag Ethanolamine Tablets, Proline Henggliflozin Tablets, Isethionate Dalcili acid tablets were approved for marketi.
Up to now, the number of innovative drugs on the market has increased to 10, more than 60 innovative drugs are under clinical development, and more than 250 clinical trials are being carried out at home and abro.
The overseas market is a major layout of the compa.
In 2021, Hengrui Medicine will continue to strengthen the implementation of its internationalization strate.
During the reporting period, overseas R&D investment totaled 236 billion yuan, accounting for 193% of the total R&D investme.
At present, the company has a total of more than 170 overseas R&D tea.
During the reporting period, nearly 20 international clinical trials were carried out, and overseas registration applications were continu.
Following closely behind Hengrui are CSPC and Zhongsheng Pharmaceutical, with R&D investment of about 1
Among them, CSPC will invest 422 billion yuan in research and development in 2021, and achieve a revenue of 268 billion yuan (patented drugs), and its research and development investment will account for 11% of its revenue; Zhongsheng Pharmaceutical will invest 82 billion yuan in research and development in 2021, with a revenue of 286 billion yu.
, R&D investment accounted for 12% of reven.
In addition, Hansoh Pharmaceutical's revenue in 2021 is also approaching the 10 billion yuan mark, and its R&D investment in that year accounted for 11% of its reven.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
